07:53 AM EST, 11/04/2025 (MT Newswires) -- Amicus Therapeutics ( FOLD ) reported Q3 non-GAAP net income Tuesday of $0.17 per diluted share, up from $0.10 a year earlier.

Two analysts polled by FactSet expected $0.06.

Net product revenue for the quarter ended Sept. 30 was $169.1 million, up from $141.5 million a year earlier.

Analysts surveyed by FactSet expected $165.7 million.

The company reiterated its full-year 2025 guidance of total revenue growth of 15% to 22%. Analysts polled by FactSet expect $627.3 million.